Compal, a leading Taiwanese OEM, has taken a significant step into the AI medical field by signing a memorandum of cooperation with Shin Kong Hospital. The strategic partnership, announced on August 21, aims to accelerate the adoption of AI applications in the healthcare industry, starting with a project focused on using AI medical imaging to quantify pulmonary fibrosis.
In this collaboration, Compal will provide AI PCs and servers, while Shin Kong Hospital will contribute AI models and field verification. The AI technology will analyze high-resolution computed tomography (HRCT) images to improve the accuracy and efficiency of diagnosing pulmonary fibrosis, a condition associated with late-stage interstitial lung disease.
Compal’s chairman, Chen Ruicong, emphasized the company’s commitment to expanding into smart medical care, with successful commercial applications already in AI risk detection for various conditions. This partnership represents another step towards integrating AI into everyday medical practice.
Shin Kong Hospital’s Chief Information Officer, Xie Zhonghe, mentioned that the next goal is to obtain medical certification from Taiwan’s Food and Drug Administration (TFDA), paving the way for future commercial applications.
As Compal continues to strengthen its position in the medical field, the company is also exploring partnerships and business opportunities in medical technology, aiming for long-term growth and leadership in AI healthcare solutions.
